181 related articles for article (PubMed ID: 18328956)
1. Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis.
Miret J; Nascimento E; Sampaio W; França JC; Fujiwara RT; Vale A; Dias ES; Vieira E; da Costa RT; Mayrink W; Campos Neto A; Reed S
Vaccine; 2008 Mar; 26(12):1585-94. PubMed ID: 18328956
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis.
Guarga JL; Moreno J; Lucientes J; Gracia MJ; Peribáñez MA; Castillo JA
Vet Immunol Immunopathol; 2002 Sep; 88(1-2):13-20. PubMed ID: 12088640
[TBL] [Abstract][Full Text] [Related]
3. Studies on canine leishmaniasis control. 1. Evolution of infection of different clinical forms of canine leishmaniasis following antimonial treatment.
Mancianti F; Gramiccia M; Gradoni L; Pieri S
Trans R Soc Trop Med Hyg; 1988; 82(4):566-7. PubMed ID: 3076714
[TBL] [Abstract][Full Text] [Related]
4. Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.
Trigo J; Abbehusen M; Netto EM; Nakatani M; Pedral-Sampaio G; de Jesus RS; Goto Y; Guderian J; Howard RF; Reed SG
Vaccine; 2010 Apr; 28(19):3333-40. PubMed ID: 20206667
[TBL] [Abstract][Full Text] [Related]
5. Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs.
Bourdoiseau G; Bonnefont C; Hoareau E; Boehringer C; Stolle T; Chabanne L
Vet Immunol Immunopathol; 1997 Oct; 59(1-2):21-30. PubMed ID: 9437823
[TBL] [Abstract][Full Text] [Related]
6. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
7. Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment.
Solano-Gallego L; Riera C; Roura X; Iniesta L; Gallego M; Valladares JE; Fisa R; Castillejo S; Alberola J; Ferrer L; Arboix M; Portús M
Vet Parasitol; 2001 Apr; 96(4):265-76. PubMed ID: 11267753
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis.
Oliva G; Gradoni L; Cortese L; Orsini S; Ciaramella P; Scalone A; de Luna R; Persechino A
Ann Trop Med Parasitol; 1998 Mar; 92(2):165-71. PubMed ID: 9625912
[TBL] [Abstract][Full Text] [Related]
9. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment.
Gramiccia M; Gradoni L; Orsini S
Ann Trop Med Parasitol; 1992 Dec; 86(6):613-20. PubMed ID: 1304703
[TBL] [Abstract][Full Text] [Related]
10. Value of Western blotting in the clinical follow-up of canine leishmaniasis.
Fernández-Pérez FJ; Méndez S; de la Fuente C; Cuquerella M; Gómez MT; Alunda JM
J Vet Diagn Invest; 1999 Mar; 11(2):170-3. PubMed ID: 10098690
[TBL] [Abstract][Full Text] [Related]
11. Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites.
Deplazes P; Smith NC; Arnold P; Lutz H; Eckert J
Parasite Immunol; 1995 Sep; 17(9):451-8. PubMed ID: 8552413
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis.
Cardoso JMO; Brito RCF; Mathias FAS; Reis LES; Vieira JFP; Ostolin TLVDP; Andrade HM; Ramos GS; Frézard F; Aguiar-Soares RDO; Roatt BM; Reis AB
Mol Immunol; 2022 Jan; 141():70-78. PubMed ID: 34814056
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum.
Valladares JE; Riera C; Alberola J; Gállego M; Portús M; Cristòfol C; Franquelo C; Arboix M
Vet Parasitol; 1998 Feb; 75(1):33-40. PubMed ID: 9566092
[TBL] [Abstract][Full Text] [Related]
14. Early reduction of Leishmania infantum-specific antibodies and blood parasitemia during treatment in dogs with moderate or severe disease.
Solano-Gallego L; Di Filippo L; Ordeix L; Planellas M; Roura X; Altet L; Martínez-Orellana P; Montserrat S
Parasit Vectors; 2016 May; 9(1):235. PubMed ID: 27160317
[TBL] [Abstract][Full Text] [Related]
15. Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy.
Alvar J; Molina R; San Andrés M; Tesouro M; Nieto J; Vitutia M; González F; San Andrés MD; Boggio J; Rodriguez F
Ann Trop Med Parasitol; 1994 Aug; 88(4):371-8. PubMed ID: 7979624
[TBL] [Abstract][Full Text] [Related]
16. Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate.
Riera C; Valladares JE; Gállego M; Aisa MJ; Castillejo S; Fisa R; Ribas N; Carrió J; Alberola J; Arboix M
Vet Parasitol; 1999 Jul; 84(1-2):33-47. PubMed ID: 10435789
[TBL] [Abstract][Full Text] [Related]
17. Exploitation of parasite-derived antigen in therapeutic success against canine visceral leishmaniosis. Veterinary Group of Lupino.
Neogy AB; Vouldoukis I; da Costa JM; Monjour L
Vet Parasitol; 1994 Sep; 54(4):367-73. PubMed ID: 7839561
[TBL] [Abstract][Full Text] [Related]
18. Potential of Artesunate in the treatment of visceral leishmaniasis in dogs naturally infected by Leishmania infantum: Efficacy evidence from a randomized field trial.
Medkour H; Bitam I; Laidoudi Y; Lafri I; Lounas A; Hamidat HK; Mekroud A; Varloud M; Davoust B; Mediannikov O
PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008947. PubMed ID: 33338041
[TBL] [Abstract][Full Text] [Related]
19. Hepatic fibropoiesis in dogs naturally infected with Leishmania (Leishmania) infantum treated with liposome-encapsulated meglumine antimoniate and allopurinol.
Castro RS; de Amorim IFG; Pereira RA; Silva SM; Pinheiro LJ; Pinto AJW; Azevedo EG; Demicheli C; Caliari MMV; Mosser DM; Michalick MSM; Frezard FJG; Tafuri WL
Vet Parasitol; 2018 Jan; 250():22-29. PubMed ID: 29329619
[TBL] [Abstract][Full Text] [Related]
20. Evolution of serum albumin/globulin ratio after antimonial therapy in canine leishmaniasis.
Amusategui I; Sainz A; Tesouro MA
Ann N Y Acad Sci; 1998 Jun; 849():447-9. PubMed ID: 9668510
[No Abstract] [Full Text] [Related]
[Next] [New Search]
